Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott GmbH & Co. KG

Division of Abbott Laboratories Inc.
www.abbott.de

Latest From Abbott GmbH & Co. KG

Deal Statistics Quarterly, Q2 2001

In Vivo presents another installment of our quarterly review of dealmaking--in this case April 2001-June 2001. Our data comes from Windhover's Strategic Transactions Database. We include medical device financings by industry segment and by deal type; medical device M&A; diagnostic financings and alliances by product category; pharma and biotech alliances by technology segment; pharma and biotech alliances by deal type, and pharma and biotech financings by market segment and therapeutic category.
BioPharmaceutical Medical Device

Serono's Global Ambitions

Serono, Europe's biggest biotechnology company, is nearly one hundred years old. Recently, the company has been on a quest to establish a public image quite different from that of a traditional, family-owned pharmaceutical group. Driving Serono into the public eye is Ernesto Bertarelli, who took the helm from his father in 1996. The structural changes he brought about provided the framework for modernization. But Serono still has to make its mark in the US, where the most important determinant of success will be the timing of its launch of Rebif, its multiple sclerosis drug.
BioPharmaceutical Strategy

Deal Statistics Quarterly, Nov 2000-Jan 2001

In Vivo presents another installment of our quarterly review of dealmaking--in this case November 2000-January 2001. Our data comes from Windhover's Strategic Transactions Database. We include medical device financings by industry segment and by deal type; medical device M&A; diagnostic financings and alliances by product category; pharma and biotech alliances by technology segment; pharma and biotech alliances by deal type, and pharma and biotech financings by market segment and therapeutic category.
BioPharmaceutical Medical Device

Albany Molecular's Next Act

In the fast-growing chemistry services market, Albany Molecular has proven itself a steady and, in recent times, superlative performer. Albany Molecular is capitalizing on its growing revenue stream and strong market performance by building up chemistry capabilities to provide one-stop, albeit specialty, shopping. But the company's growth and above-average margins stem largely from its one major royalty deal, on Allegra--and the company has been spending its time on services, not on at-risk deals.Recent acquisitions position Albany Molecular to provide more proprietary technologies: the key is whether the company's management is willing to take the financial risk of deals in which it has to fund its own early development in order to win an important piece of a product's upside and thus boost it service-company margins.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Knoll AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • Harald Eistetter, Dir. Biotech Liaisons
    Steven Koehler, VP, Fin. & Info.
  • Contact Info
  • Abbott GmbH & Co. KG
    Phone: (49) 6122 580
    Max-Planck-Ring 2
    Wiesbaden-Delkenheim, 65205
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register